HLA-I loss in germ cell tumors of the testis: potential implications for immune evasion, preservation of the stem cell phenotype, and reprogramming.

Authors

Marco Grillini, Agnese Orsatti, Francesca Ambrosi, Antonio De Leo, Francesco Vasuri, Federico Mineo Bianchi, Veronica Mollica, Francesco Massari, Joao Lobo, Nuno Tiago Tavares, Fernanda Fernandes-Pontes, Andres M Acosta, Maurizio Colecchia, Ezra Baraban, Michelangelo Fiorentino, Costantino Ricci

Published in

Pathobiology : journal of immunopathology, molecular and cellular biology. Pages 1. Sep 29, 2026. Epub Sep 29, 2026.

Abstract

Previous studies have analyzed the "reprogramming" of germ cell tumors of the testis (GCTT), which is a complex genetic/epigenetic process regulated by tumor microenvironment (TME) and resulting in the preservation of stem cell features and/or the differentiation of GCTT. Human leukocyte antigens class I (HLA-I) is a key regulator of the interactions between tumor cells and TME, but few studies have studied its expression in GCTT, germ cell neoplasia in situ (GCNIS), and "normal" adjacent testis (AT).
We tested 102, 41 and 26 GCTT components, GCNIS, and AT, respectively. HLA-I expression was scored (intact/retained, sub-clonal loss, and complete loss), dichotomized, and compared between different subgroups by adopting Fisher's exact test.
We found that HLA-I loss was more frequent in seminoma (S) and embryonal carcinoma (EC) rather than in the other non-seminomatous GCTT (NS-GCTT) (p<0.001 and p: 0.002). HLA-I was positive in all GCNIS (41/41, 100%), thus being statistically significant compared to both GCTT (p<0.001) and AT (p<0.001). HLA-I loss was found in all AT (26/26, 100%), with a characteristic "patterned" expression (loss in spermatids, spermatozoa, and spermatogonia; expressed by spermatocytes).
"HLA-I loss" varies during the GCTT reprogramming, thus supporting its role in the crosstalk between TME and GCTT, which is crucial for the maintenance of stem cell features (S and EC) and specific differentiation programs (other NS-GCTT). Future studies are needed to explore its role in GCNIS and AT.

PMID:
42809511
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.